ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1705

The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users

Marco Gianpiero Antivalle1, Michele Agosti1, Giuliana La Paglia2, Alberto Batticciotto3, Maria Chiara Ditto4, SIMONE PARISI5 and Piercarlo Sarzi-Puttini6, 1L. Sacco University Hospital, Milano, Italy, 2L.Sacco University Hospital, Milano, Lombardia, Italy, 3Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, 4AOU Città della Salute e della Scienza, Torino, Italy, 5AOU Città della Salute e della Scienza, TURIN, Italy, 6L.Sacco University Hospital, Milano, Italy

Meeting: ACR Convergence 2021

Keywords: Drug-Drug Interference, Hydroxychloroquine, QT Interval

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has been questioned, following controversial reports of cardiac toxicity, possibly related to a prolongation of the QT interval. Furthermore, it was recently shown that concomitant administration of different drugs can affect QT interval in hydroxychloroquine chronic users.

Methods: 12-lead electrocardiograms were recorded in 355 ambulatory patients (SLE = 85, RA = 80, SSc = 71, UCTD = 68, other CTDs = 51). The analysis was performed on corrected QT intervals (QTc) calculated according to Framingham formula (QTc = QT+0.154 (1−RR)), with ULN = 449 ms in males, and 467 ms in females. Glomerular filtrate rate (eGFR) was calculated with the CKD-EPI equation. The influence on QTc values of demographic variables, chronic (≥3 months) HCQ treatment, and of the use of 23 comedications -including corticosteroids, immunosuppressants, biologics, statins, aspirin, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, betablockers, endothelin antagonists, duloxetine, selective serotonin reuptake inhibitors, gabapentinoids, proton-pump inhibitors (PPI), calcium channel blockers (CCBs) – were evaluated by parametric or non parametric statistical methods, as appropriate. All statistic analyses were performed with the IBM SPSS statistical package version 25.

Results: Demographic variables, and the use of comedications were not different in HCQ+ and HCQ- patients (Table 1). In the whole population, the QTc mean duration was 416.44 ± 19.53 ms, and was correlated with age (Fig. 1; r = 0.211, p < 0.001), but not with gender (F: 417.79±19.02 ms, M: 413.21±23.73 ms, p = 0.303), eGFR (r = -0.83, p = 0.120), BMI (-0.001, p = 0.984) or disease (p = 0.139). In only 4 patients (HCQ+: 3 (1.5%) – HCQ-: 1 (0.6%), p = 0.629) QTc duration was above ULN.

The patients were heavily cotreated, with 5.64 ± 3.47 concomitant medications on average (HCQ+ 5.58±3.47; HCQ- 5.59±3.33, p=0.804). Among the 23 cotreatments evaluated in univariate analyses, QTc duration was associated only with the assumption of vitamin D (418.95±19.56 ms vs 411.38±18.53 ms, p = 0.001), PPIs (419.14±20.00 ms vs 412.89±16.86 ms, p = 0.003), and CCBs (421.61±24.41 ms vs 415.53±18.44 ms, p = 0.036). In the analysis of covariance on age-adjusted data, only HCQ (p < 0.001) and Vitamin D (p =0.046) but not PPIs (p = 0.121) nor CCBs (p = 0.200) were still significantly correlated to QTc interval. Furthermore, as reported in Fig. 2, our data show a trend - albeit not statistically significant - towards an additive effect on QT prolongation of the association of Vitamin D, PPIs and CCBs with HCQ, even more evident in the case of association of the 3 drug classes.

Conclusion: In this study, the QTc interval duration was correlated to age and was significantly prolonged in patients treated with hydroxychloroquine as compared to controls, although significant prolongation was extremely infrequent. Furthermore, our data revealed signs of drug-drug interference, suggesting that regular monitoring of the electrocardiogram is advisable in these patients, often undergoing cotreatment with multiple drugs.

Tab. 1. Demographic and clinical variables in patients treated with HCQ (HCQ+) and in controls (HCQ-).

Fig 1. Correlstion between age and Qtc interval

Fig. 2. Influence of selected cotreatments in patients treated with HCQ and in controls


Disclosures: M. Antivalle, None; M. Agosti, None; G. La Paglia, None; A. Batticciotto, None; M. Ditto, None; S. PARISI, None; P. Sarzi-Puttini, None.

To cite this abstract in AMA style:

Antivalle M, Agosti M, La Paglia G, Batticciotto A, Ditto M, PARISI S, Sarzi-Puttini P. The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-age-and-drug-drug-interactions-on-qt-interval-in-chronic-hydroxychloroquine-users/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-age-and-drug-drug-interactions-on-qt-interval-in-chronic-hydroxychloroquine-users/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology